Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

108.41 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Why Axsome Therapeutics Stock Is Crashing Today
An unexpected regulatory setback is weighing on the biotech's shares today. 
Via The Motley Fool
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET Monday, 63 stocks made new 52-week lows. Intriguing Points: The largest company by market cap to set a new 52-week low was PACCAR (NASDAQ:PCAR).... 
Via Benzinga
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Thinking About Buying Stock In Immunome, Axsome Or Etsy?
Immunome Inc (NASDAQ:IMNM) shares are trading higher by 9.25% by $32.28 after the ... 
Via Benzinga
Axsome Stock Drops To 52-Week Low On FDA Response Letter For Depression Candidate
Wrapped up in its Q2 earnings release, Axsome Therapeutics Inc (NASDAQ: AXSM) said that on July 30, it received an FDA letter for a marketing application for AXS-... 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; DISH Network Profit Beats Estimates
Following the market opening Monday, the Dow traded down 0.19% to 35,141.90 while the NASDAQ rose 0.10% to 14,850.40. The S&P also fell, dropping 0.07% to 4,433.63. The U.S.... 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Windtree Therapeutics (NASDAQ:WINT) stock rose 30.38% to $2.36 during Monday's pre-market session. The company's market cap stands at $61.9 million. The... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
On Friday morning, 33 companies hit new 52-week lows. Areas of Significance: The largest company in terms of market cap to set a new 52-week low was Las Vegas Sands... 
Via Benzinga
Is There Any Hope Left for Axsome Therapeutics?
After a fantastic run-up, investors are now losing faith in this emerging biotech's stock. 
Via The Motley Fool
Why Shares of Axsome Therapeutics Are Falling Today
The FDA took back a beneficial designation but management isn't changing its plans. 
Via The Motley Fool
Buy This Stock Before Everyone Else Does
This biotech has significant upside left. 
Via The Motley Fool
Ditch Dogecoin: These 3 Stocks Could Double Your Money
The path to a twofold or greater return is straightforward for each of these stocks. 
Via The Motley Fool
Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022
After a pre-NDA meeting with FDA, Axsome Therapeutics Inc (NASDAQ: AXSM) has announced its plan to submit a marketing application seeking approval for AXS-14... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 10, 2021
Upgrades According to Argus Research, the prior rating for Zoom Video Communications Inc (NASDAQ:ZM) was changed from Hold to Buy. Zoom Video Communications earned $1.32... 
Via Benzinga
2 Top Biotech Stocks to Buy for Summer 2021
Progress in these companies' drug development pipelines should give shareholders plenty to look forward to. 
Via The Motley Fool
Axsome Therapeutics, Inc. (AXSM) Q1 2021 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Parkinson’s Disease Therapeutic Market Revenue Is Expected To Cross $8 Billion By 2027
Via FinancialNewsMedia
2 Top Biotech Stocks to Buy Right Now
The stocks of Novavax and Axsome Therapeutics are soaring. Here's why. 
Via The Motley Fool
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
3 Biotech Stocks That Could Be Millionaire-Makers
Their stocks have collapsed. But they could still be huge winners. 
Via The Motley Fool
58 Biggest Movers From Yesterday
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company announced the full details of its Phase 2 trial... 
Via Benzinga
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR... 
Via Benzinga
Why Axsome Therapeutics Stock Is Jumping Today
The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate. 
Via The Motley Fool
38 Stocks Moving In Monday's Mid-Day Session
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) surged 46.9% to $6.25 after the company announced the full details of its Phase 2 trial evaluating its lead drug... 
Via Benzinga
FDA Begins Priority Review of Axsome Therapeutics' Potential New Depression Drug
The first new treatment for millions of Americans with major depressive disorder could become available this summer. 
Via The Motley Fool
Axsome Stock Jumps After Snagging Priority Review For Depression Drug
Axsome Therapeutics snagged a speedy review from the FDA for its depression treatment on Monday, leading Axsome stock to gap higher. 
Via Investor's Business Daily
AXSM Stock: The Big FDA News Giving Axsome Therapeutics a Boost
AXSM stock is gaining on Monday after the FDA granted its new drug application priority review. Here's what you should know now. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Ocugen (NASDAQ:OCGN) shares rose 13.81% to $10.96 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Advaxis... 
Via Benzinga
Axsome Therapeutics Stock Jumps As FDA Accepts AXS-05 Application In Major Depressive Disorder
Under Priority review status, the FDA has accepted Axsome Therapeutics Inc's (NASDAQ: AXSM) marketing application for AXS-05 for major depressive disorder (MDD... 
Via Benzinga
< Previous 1 2
...
16 17 18 19 20 21 22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.